As of November 27, Zai Lab Limited (NASDAQ:ZLAB) is a consensus Buy with over 90% analysts covering it having a Buy, Strong Buy, or equivalent rating. With a consensus 1-year average price target of ...
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that ...
If you want to know who really controls Zai Lab Limited (NASDAQ:ZLAB), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around ...
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for full-year 2023, along with recent product highlights and corporate ...
Hosted on MSN
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug
Zai Lab (ZLAB) announced on Wednesday that it plans to await the results of a trial evaluating Bemarituzumab in combination with Nivolumab and chemotherapy before filing for regulatory approval of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results